Metronidazole-loaded polydopamine nanomedicine with antioxidant and antibacterial bioactivity for periodontitis.

Abstract

Aim: This study focused on treating periodontitis with bacterial infection and local overaccumulation ofreactive oxygen species. Materials & methods: Polydopamine nanoparticles (PDA NPs) were exploited asefficient carriers for encapsulated metronidazole (MNZ). The therapeutic efficacy and biocompatibilityof PDA@MNZ NPs were investigated through both in vitro and in vivo studies. Results: The nanodrugPDA@MNZ NPs were successfully fabricated, with well-defined physicochemical characteristics. In vitro, the PDA@MNZ NPs effectively eliminated intracellular reactive oxygen species and inhibited the growthof Porphyromonas gingivalis. Moreover, the PDA@MNZ NPs exhibited synergistic therapy for periodontitisin invivo. Conclusion: PDA@MNZ NPs were confirmed with exceptional antimicrobial and antioxidantfunctions, offering a promising avenue for synergistic therapy in periodontitis.